company background image

Beauty Health NasdaqCM:SKIN Stock Report

Last Price


Market Cap







30 Sep, 2022


Company Financials +
SKIN fundamental analysis
Snowflake Score
Future Growth5/6
Past Performance0/6
Financial Health4/6

SKIN Stock Overview

The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide.

Beauty Health Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Beauty Health
Historical stock prices
Current Share PriceUS$11.79
52 Week HighUS$30.17
52 Week LowUS$9.95
1 Month Change1.64%
3 Month Change-8.39%
1 Year Change-55.51%
3 Year Changen/a
5 Year Changen/a
Change since IPO8.77%

Recent News & Updates

Sep 27

Beauty-Health Company announces $200M buyback program

Beauty-Health Company (NASDAQ:SKIN) stated Tuesday it has secured Board's approval to repurchase up to $200M common shares. It includes accelerated share repurchase agreement with JPMorgan Chase to buyback $100M shares, resulting in initial delivery of ~7.7M SKIN's shares on Sept. 29, 2022 with final settlement expected in Q1 2023. The company expects to fund the repurchase with cash on-hand. Earlier: The Beauty Health reports Q2 mixed earnings; raises FY22 guidance

Shareholder Returns

SKINUS Personal ProductsUS Market

Return vs Industry: SKIN underperformed the US Personal Products industry which returned -31.6% over the past year.

Return vs Market: SKIN underperformed the US Market which returned -21.5% over the past year.

Price Volatility

Is SKIN's price volatile compared to industry and market?
SKIN volatility
SKIN Average Weekly Movement11.3%
Personal Products Industry Average Movement9.4%
Market Average Movement6.9%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market2.8%

Stable Share Price: SKIN is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: SKIN's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

1997704Andrew Stanleick

The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company’s flagship product includes HydraFacial that enhance the skin to cleanse, peel, exfoliate, extract, infuse, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a HydraFacial Delivery System designed to elevate every part of the treatment and connects providers to the consumer’s preferences to create a more personalized experience; HydraFacial Nation App, an app that allows consumers to learn about their skin health, discover treatment options, and track their treatments over time; and Keravive, a treatment for scalp health.

Beauty Health Fundamentals Summary

How do Beauty Health's earnings and revenue compare to its market cap?
SKIN fundamental statistics
Market CapUS$1.78b
Earnings (TTM)-US$192.02m
Revenue (TTM)US$324.99m


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SKIN income statement (TTM)
Cost of RevenueUS$98.56m
Gross ProfitUS$226.43m
Other ExpensesUS$418.45m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date


Earnings per share (EPS)-1.27
Gross Margin69.67%
Net Profit Margin-59.08%
Debt/Equity Ratio208.4%

How did SKIN perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.


Is SKIN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 3/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SKIN?

Other financial metrics that can be useful for relative valuation.

SKIN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue5.3x
Enterprise Value/EBITDA-219x
PEG Ration/a

Price to Sales Ratio vs Peers

How does SKIN's PS Ratio compare to its peers?

SKIN PS Ratio vs Peers
The above table shows the PS ratio for SKIN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average1.8x
NUS Nu Skin Enterprises
MED Medifast
EPC Edgewell Personal Care
ELF e.l.f. Beauty
SKIN Beauty Health

Price-To-Sales vs Peers: SKIN is expensive based on its Price-To-Sales Ratio (5.5x) compared to the peer average (1.8x).

Price to Earnings Ratio vs Industry

How does SKIN's PE Ratio compare vs other companies in the US Personal Products Industry?

Price-To-Sales vs Industry: SKIN is expensive based on its Price-To-Sales Ratio (5.5x) compared to the US Personal Products industry average (1x)

Price to Sales Ratio vs Fair Ratio

What is SKIN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SKIN PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio5.5x
Fair PS Ratio2.5x

Price-To-Sales vs Fair Ratio: SKIN is expensive based on its Price-To-Sales Ratio (5.5x) compared to the estimated Fair Price-To-Sales Ratio (2.5x).

Share Price vs Fair Value

What is the Fair Price of SKIN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SKIN ($11.79) is trading below our estimate of fair value ($36.93)

Significantly Below Fair Value: SKIN is trading below fair value by more than 20%.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Future Growth

How is Beauty Health forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?

Future Growth Score


Future Growth Score 5/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SKIN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).

Earnings vs Market: SKIN is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: SKIN is expected to become profitable in the next 3 years.

Revenue vs Market: SKIN's revenue (20.5% per year) is forecast to grow faster than the US market (7.6% per year).

High Growth Revenue: SKIN's revenue (20.5% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: SKIN's Return on Equity is forecast to be low in 3 years time (15.8%).

Discover growth companies

Past Performance

How has Beauty Health performed over the past 5 years?

Past Performance Score


Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: SKIN is currently unprofitable.

Growing Profit Margin: SKIN is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: SKIN is unprofitable, and losses have increased over the past 5 years at a rate of 57.1% per year.

Accelerating Growth: Unable to compare SKIN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SKIN is unprofitable, making it difficult to compare its past year earnings growth to the Personal Products industry (-4.8%).

Return on Equity

High ROE: SKIN has a negative Return on Equity (-54.5%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is Beauty Health's financial position?

Financial Health Score


Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: SKIN's short term assets ($995.8M) exceed its short term liabilities ($87.1M).

Long Term Liabilities: SKIN's short term assets ($995.8M) exceed its long term liabilities ($775.6M).

Debt to Equity History and Analysis

Debt Level: SKIN has more cash than its total debt.

Reducing Debt: Insufficient data to determine if SKIN's debt to equity ratio has reduced over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SKIN has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if SKIN has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.

Discover healthy companies


What is Beauty Health current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Beauty Health Dividend Yield vs Market
How does Beauty Health dividend yield compare to the market?
SegmentDividend Yield
Company (Beauty Health)n/a
Market Bottom 25% (US)1.7%
Market Top 25% (US)4.7%
Industry Average (Personal Products)1.3%
Analyst forecast in 3 Years (Beauty Health)n/a

Notable Dividend: Unable to evaluate SKIN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SKIN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SKIN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SKIN's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as SKIN has not reported any payouts.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Andrew Stanleick (51 yo)



Mr. Andrew Stanleick serves as President, Chief Executive Officer and Director of The Beauty Health Company since February 7, 2022. He was Chief Executive Officer of Kylie Jenner Beauty Brands at Coty Inc....

Leadership Team

Experienced Management: SKIN's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.

Board Members

Experienced Board: SKIN's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of SKIN?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders13,890,3998.1%
VC/PE Firms36,568,00221.5%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 13.1%.

Top Shareholders

Top 25 shareholders own 98.01% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
Linden LLC
36,568,002$431.1m0%no data
The Vanguard Group, Inc.
9,684,147$114.2m1.65%no data
Janus Henderson Group plc
Brenton L. Saunders
8,365,820$98.6m0.06%no data
Baron Capital Group, Inc.
BlackRock, Inc.
6,452,166$76.1m-17.05%no data
William Blair Investment Management, LLC
Redmile Group, LLC
Luxor Capital Group, LP
Soleus Capital Management, L.P.
Senvest Management, LLC
Wellington Management Group LLP
DW Management Services, LLC
2,600,391$30.7m0%no data
Driehaus Capital Management LLC
Clinton Carnell
2,470,174$29.1m0%no data
Manisha Narasimhan
2,265,021$26.7m0%no data
Lord, Abbett & Co. LLC
Invesco Ltd.
Geode Capital Management, LLC
1,781,615$21.0m8.95%no data
Victory Capital Management Inc.
State Street Global Advisors, Inc.
1,749,705$20.6m3.13%no data
Eagle Asset Management, Inc.
Woodline Partners LP
Bridger Management LLC

Company Information

The Beauty Health Company's employee growth, exchange listings and data sources

Key Information

  • Name: The Beauty Health Company
  • Ticker: SKIN
  • Exchange: NasdaqCM
  • Founded: 1997
  • Industry: Personal Products
  • Sector: Household
  • Implied Market Cap: US$1.779b
  • Shares outstanding: 150.89m
  • Website:

Number of Employees


  • The Beauty Health Company
  • 2165 Spring Street
  • Long Beach
  • California
  • 90806
  • United States


TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
V7A0DB (Deutsche Boerse AG)YesClass A Common StockDEEURNov 2020
SKINNasdaqCM (Nasdaq Capital Market)YesClass A Common StockUSUSDNov 2020

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/30 00:00
End of Day Share Price2022/09/30 00:00
Annual Earnings2021/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.